Nikolai Bespalov

Nikolai Bespalov is a director of development at RNC Pharma, an analytical company specializing in the pharmaceutical market. He is known for providing insights into the supply and demand of essential medications, particularly in relation to the current challenges facing the availability of carbamazepine and its derivatives in Russia.

Global Media Ratings

Dominance

0.00%

Persistence

0 wks

Reach

135,947

Power

1,415$

Sentiment

5.00

Countries Mentioned

Country	Mentions	Sentiment	Dominance	+ Persistence	x Population	= Reach	x GDP (millions)	= Power
Russia	1	5.00	0.09%	+0%	144,104,080	135,947	$1,500,000	1,415$
Totals	1				144,104,080	135,947	$1,500,000	1,415$

Interactive World Map

Each country's color is based on "Mentions" from the table above.

Recent Mentions

Russia: Nikolai Bespalov, the director of development at RNC Pharma, stated that the supply of anti-Rh immunoglobulin does not meet the country's full needs. 5

Elena Ordiants

RBC: Аналитики зафиксировали рост цен на иммуноглобулин для беременных — РБК

Russia: Nikolai Bespalov is the director of development at an analytical company who estimated the daily revenue of pharmacy networks. 5

Mikhail Grebenshchikov Sergey Shulyak Alexey Kozlov Kirill Levkin Mikhail Khlebunov Denis Alekhin Maxim Lagutin

RBC: К чему приведет хакерская атака на аптечные сети и «Семейного доктора» — РБК

Russia: Nikolai Bespalov noted that the revenue figures provided by 'Kontur.Fokus' include the entire volume of the company's business. 7

RBC: В России сократилось количество новых фармкомпаний — РБК

Russia: Nikolai Bespalov is the director of development at RNC Pharma who noted the growth in pharmacy sales. 7

Sergey Shulyak Vasiliy Danilchik

RBC: Аналитики увидели возвращение потребления лекарств к доковидному уровню — РБК